December 30, 2021
Life Sciences
  • Johnson & Johnson announced that two clinical trials found that its booster shot offered strong protection against Omicron. Data from one real-life study from South Africa showed vaccine effectiveness against hospitalization from Covid-19 rose to 85 percent after a booster dose of the J&J vaccine, even after the Omicron variant was circulating. Data from a lab-based study in the U.S. indicated the vaccine stimulates a strong immune response from T-cells, which protect people against severe disease even if they don’t block the virus entirely from infecting the body. (Articles here, here, and here)